8月21日晚间,欧康维视生物(股票代码:01477.HK,下称“公司”)发布2025年中期业绩报告。上半年,公司实现营业收入2.94亿元,同比大幅增长75.4%;经调整亏损额1.08亿元,毛利润持续增加,账面结余资金达5.78亿元。业绩高增的核心动能源于多款核心产品的稳定放量,其中从爱尔康引进的多款商业化产品在年内顺利整合,为公司开辟了显著的增量业务空间;财务状况和资本结构方面展现出较强的支撑力,...
Source Link8月21日晚间,欧康维视生物(股票代码:01477.HK,下称“公司”)发布2025年中期业绩报告。上半年,公司实现营业收入2.94亿元,同比大幅增长75.4%;经调整亏损额1.08亿元,毛利润持续增加,账面结余资金达5.78亿元。业绩高增的核心动能源于多款核心产品的稳定放量,其中从爱尔康引进的多款商业化产品在年内顺利整合,为公司开辟了显著的增量业务空间;财务状况和资本结构方面展现出较强的支撑力,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.